Radioimmunolymphoscintigraphy in the preoperative staging of primary breast cancer: A pilot study using a human monoclonal antibody (LiLo-16.88)

International Journal of Oncology

Volumn 9, Issue 4, 1996, Pages 659-667

  Pecking, Alain P ^a   Gougeon Bertrand, Françoise J ^a   Lokiec, François M ^a   Murray, James H ^b   Subramanian, Ramaswamy ^b   Boudinet, Alain ^a   Floiras, Jean L ^a   Haspel, Martin V ^b   Klein, Jerry L ^b   Shaban, Samir ^b   De Jager, Robert L ^b   Hanna Jr , Michael G ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b Perimmune Inc   (United States)

Author keywords

breast cancer; human monoclonal antibodies; lymph node; staging

Indexed keywords

ANTIBODY LILO 16 88; HUMAN MONOCLONAL ANTIBODY; INDIUM 111; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; LYMPH NODE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029794798     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fisher B, Wolmark N, Redmond C, et al: Findings from NSABP protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer 48: 1863-1872, 1981.
2. Gabelle PH, Comet M, Bodin JP, et al: La lymphoscintigraphie mammaire par injection intra-tumorale dans le bilan du cancer du sein. Nouv Presse Med 10: 3067-3070, 1981.
3. Ege GN: Internal mammary lymphoscintigraphy. Radiology 118: 101-107, 1976.
4. MacLean RG and Ege GN: Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients. J Nucl Med 27: 1116-1124, 1986.
5. DeLand FH, Kim EE, Corgan RL, et al: Axillary lymphoscintigraphy by radioimmunodetection of carcinoembryonic antigen in breast cancer. J Nucl Med 20: 1243-1250, 1979.
6. Keenan AM, Harbert JC and Larson SM: Monoclonal antibodies in nuclear medicine. J Nucl Med 26: 531-537, 1985.
7. Epenetos AA, Britton KE, Mather S, et al: Targeting of iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet 2: 999-1003, 1982.
8. Rainsbury RM: The localization of human breast carcinomas by radiolabelled monoclonal antibodies. Br J Surg 71: 805-812, 1984.
9. Lamki LM, Buzdar AU, Singletary SE, et al: Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer. A phase I study. J Nucl Med 32: 1326-1332, 1991.
10. Thompson CH, Stacker SA, Salehi N, et al: Immunoscintigraphy for detection of lymph node metastases from breast cancer. Lancet 2: 1245-1247, 1984.
11. Keenan AM, Weinstein JN, Mulshine JL, et al: Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. J Nucl Med 28: 42-48, 1987.
12. Steis RG, Carrasquillo JA, McCabe RP, et al: Toxicity, immunogenicity and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8: 476-490, 1990.
13. 131I-labeled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients and the influence of excess unlabeled 16.88. Eur J Cancer 27: 1430-1436, 1991.
14. Haspel MV, McCabe RP, Pomato N, et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45: 3951-3961, 1985.
15. Pomato N, Murray JH, Bos E, et al: Identification and characterization of a human colon tumor-associated antigen, CTAA 16.88, recognized by a human monoclonal antibody. In: Human Tumor Antigens and Specific Tumor Therapy. Metzger R and Mitchell M (eds). Alan R. Liss Inc., New York, NY, pp127-136, 1989.
16. Subramanian R, Colony J, Shaban S, et al: New chelating agent for attaching indium-111 to monoclonal antibodies: in vitro and in vivo evaluation. Bioconjugate Chemistry 3: 248-266, 1992.
17. Connever WJ: Practical Non-Parametric Statistics. John Wiley and Son, Inc., pp245-249, 1971.
18. Schlom J, Greiner J, Horan H, et al: Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer. Cancer Res 54: 2777-2794, 1984.
19. Epenetos AA, Snook D, Durbin H, et al: Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46: 3183-3191, 1986.
20. Sterns EE and Cochran AJ: Monoclonal antibodies in the diagnosis and treatment of carcinoma of the breast. Surg Gynecol Obstet 169: 81-98, 1989.
21. Weinstein JN, Parker RJ, Keenan AM, et al: Monoclonal antibodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. Science 218: 1334-1337, 1982.
22. Wahl RL, Geatti O, Liebert M, et al: Kinetics of interstitially administered monoclonal antibodies for purposes of lymphoscintigraphy. J Nucl Med 28: 1736-1744, 1987.
23. Keenan AM: Immunolymphoscintigraphy. Semin Nucl Med XIX: 322-331, 1989.
24. 2 fragments for the preoperative staging of breast cancers. In: Breast Cancer Immunodiagnosis and Immunotherapy. Ceriani R (ed). Plenum Press, New York, NY, pp203-210, 1989.
25. 99mTc-labeled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer. Cancer Res 50: 949-954, 1990.
26. 111In-labeled monoclonal antibody (MAS) against a mucine-like antigen. Cancer Res 50: 927-931, 1990.
27. Dairkee SH and Hackett AJ: Internal antigens accessible in breast cancer: implications for tumor targeting. J Natl Cancer Inst 80: 1216-1220, 1988.
28. Chou CF, Riopel CL and Omary MB: Identification of a keratin-associated protein that localizes to a membrane compartment. Biochem J 298: 457-463, 1994.
29. Godfroid E, Geuskens M, Dupressoir T, et al: Cytokeratins are exposed on the outer surface of established mammary carcinoma cells. J Cell Sci 99: 595-607, 1991.
30. Taddei-Peters WC, Haspel MV, Vente P, et al: Quantitation of human tumor-reactive monoclonal antibody 16.88 in the circulation and localization of 16.88 in colorectal metastatic tumor tissue using murine antiididtypic antibodies. Cancer Res 52: 2603-2609, 1992.
31. Hendler FJ and House D: Presence of breast cancer antigens in uninvolved axillary lymph nodes. Cancer Res 45: 3005-3010, 1986.
32. Hayashi N, Arakawa H, Nagase H, et al: Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res 54: 3854-3856, 1994.
33. Noguchi S, Aihara T, Nakamori S, et al: The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 75: 1595-1600, 1994.
34. Pickren JW: Significance of occult metastases. Cancer 14: 1266-1271, 1961.
35. Triozzi PL, Kim JA, Aldrich W, et al: Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody. Cancer 73: 580-589, 1994.
36. Krag DN, Weaver DL, Alex JC, et al: Surgical resection and radiolocalization of the sentinel node in breast cancer using a gamma probe. Surg Oncol 2: 335-340, 1993.
37. Giuliano AE, Dale P, Turner RR, et al: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222: 394-401, 1995.